Hilmi Erdem Gözden

Dr. Hilmi Erdem Gözden

Hematology, Bursa Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Bursa, Turkey (Türkiye)
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Cureus
Verified
Journal Article
Open access
AGAhmet Kursad Gunes
Ahmet Kursad Gunes
Hilmi Erdem GözdenHilmi Erdem Gözden
Hilmi Erdem Gözden
Neighboring the border between Turkey and Syria, Sanliurfa is one of the Turkish provinces with the highest number of Syrian refugees in our country. We aimed to find out the spectrum of beta-globin gene mutations in adult Turkish citizens and Syrian refugees with beta-thalassemia major. Of the participants, 35 patients (70%) were Turkish citizens and 15 patients (30%) were Syrian. The most common mutation in Turkish patients was found to be IVS-I-110 (G>A) with a frequency of 28.8%, followed by IVS-I-6 (T>C) with a frequency of 15.5%. Other common mutations were IVS-I-1 (G>A) and codon 39 (C>T) with frequencies of 11.1%. These four mutations accounted for 65.5% of all mutations in the Turkish cohort. The most common mutations in Syrian refugee patients were IVS-I-1 (G>A), IVS-II-1 (G>A), IVS-I-5 (G>C), and codon 5 (-CT), all with a frequency of 15.7%, accounting for 62.8% of all mutations in the Syrian patients. In the analysis, codon 5 (-CT) mutation (15.7% vs 0%, p=0.023) was found significantly higher in Syrian refugees compared to Turkish citizens. A wide spectrum of mutations was detected in beta-thalassemia major patients living in the Sanliurfa region. Mutational profiles in Turkish and Syrian patients were found to be significantly different from each other. Because marriages between Syrian refugees and Turkish citizens are increasing in our region, the genetic findings and the mutational profiles in Turkish and Syrian patients obtained in this study are thought to become useful for future prenatal molecular diagnostic tests.

16 February 2023 in Hamidiye Medical Journal
Verified
Journal Article
Closed access
EKEmrah Kılıçaslan
Emrah Kılıçaslan
SSSelim Sayın
Selim Sayın
MYMurat Yıldırım
Murat Yıldırım
TETayfun Elibol
Tayfun Elibol
HGHilmi Erdem Gözden
Hilmi Erdem Gözden
MKMuhammet Kürşat Kaptan
Muhammet Kürşat Kaptan

30 December 2022 in Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi
Verified
Journal Article
Open access
PDF file
EKEmrah Kiliçaslan
Emrah Kiliçaslan
SSSelim Sayın
Selim Sayın
MYMurat Yıldırım
Murat Yıldırım
TETayfun Eli̇bol
Tayfun Eli̇bol
HGHilmi Gözden
Hilmi Gözden
MKMuhammet Kaptan
Muhammet Kaptan
While promising results have been achieved in the treatment of childhood, the optimal initial treatment for adult acute lymphoblastic leukemia (ALL) has not yet been defined. Hyper-CVAD has become a widely used treatment for approximately 2 decades in the treatment of adult ALL. We conducted a retrospective analysis of 30 patients treated with Hyper-CVAD at two centers between 2014 and 2020. In all (n=30) patients treated with Hyper-CVAD, complete response (CR) rate was 86.7%, induction mortality was 10%, refractory disease was 3.3%, the median overall survival (OS) was 38 months (95% CI 7.78–68.2 months), the median disease-free survival (DFS) was 29 months (95% CI 9–49 months), the 2-year OS rate was 56.5%, and the 2-year DFS was rate 56.7%. For standard risk (n=12) ALL patients, the median OS was 20 months (95% CI 0–43 months), and median DFS was 7 months (95% CI 0–25 months). For high risk (n=18) ALL patients, the median OS was 38 months (95% CI 0–76 months), and median DFS was not reached. These results indicate that Hyper-CVAD regimen should be considered as an option for induction treatment of adult ALL patients who are newly diagnosed and eligible for allo-HSCT.

7 September 2026 in Cytotherapy
Verified
Journal Article
Closed access
HGHilmi Erdem Gözden
Hilmi Erdem Gözden
BOBedrettin Orhan
Bedrettin Orhan
NANihan Alkış
Nihan Alkış

22 December 2022 in Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
AÖAylin Özakgül
Aylin Özakgül
EDEsra Durmayüksel
Esra Durmayüksel
YTYasemin Gülizar Topçu
Yasemin Gülizar Topçu
HGHilmi Gözden
Hilmi Gözden
Lenfoma hastalarının Koronavirüs Hastalığı 2019 (COVID-19)’a yakalanma riskinin yüksek olduğu ve yakalanmaları halinde hastalığın seyrini kötüleştirebileceği bilinmektedir. COVID-19 hastalığı ve hematolojik kanserli hastaların bakım ve tedavisinde, multidisipliner yaklaşım önem kazanmaktadır. Multidisipliner ekipte hastanın bakımından sorumlu olan hemşireler, hemşirelik bakımını bireyselleştirilmiş ve bütüncül olarak sunmaktadır. Bu olgu sunumunda Non-hodgkin Lenfoma takipli ve COVID-19 enfeksiyonu sonucu pnömoni gelişen bir olgunun yoğun bakım ünitesindeki hemşirelik bakımı, bilimsel sorun çözümleme yöntemi olan hemşirelik süreci doğrultusunda planlanmıştır. Öksürük, ateş, halsizlik şikayetleri ile hastanenin acil kliniğine başvuran hastanın Polimeraz Zincir Reaksiyonu (PCR-Polymerase Chain Reaction) testi negatif idi. Ancak, hastanın kliniğine yatışının 37 inci gününde vücut sıcaklığının 40.1ºC ve toraks görüntülemesinde COVID-19 şüphesi olması nedeniyle yapılan PCR testi sonucu pozitif bulundu. Desatüre olarak dahiliye yoğun bakım ünitesine kabul edilen hasta, kabulünün beşinci gününde entübe edildi. Yoğun bakımda bulunduğu sürede (14 gün) hedef/beklenen hasta sonuçlarına ulaşmak için bireye özgü hemşirelik girişimleri uygulandı. Bu olgu sunumunun hemşirelere ve sağlık ekibi üyelerine rehber olacağı, aynı zamanda bakımın kalitesini arttırmak için veri olacağı düşünülmektedir.

29 October 2024 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
AEAli Erol
Ali Erol
HGHilmi Gözden
Hilmi Gözden
SKSinan Koç
Sinan Koç
HKHatice Kuzular
Hatice Kuzular
Langerhans cell histiocytosis (LCH) is a group of diseases that cause damage by local or widespread accumulation of atypical histiocytes in various tissues such as skin, bone, lung, liver, lymph nodes, mucocutaneous tissues, and endocrine organs. LCH was detected as a result of a total thyroidectomy biopsy performed on a 43-year-old female patient with a solitary euthyroid nodule following weight loss and an increase in the size of the thyroid nodule during outpatient clinic checks. Patient's whole body positron emission tomography. The case of LCH with isolated thyroid involvement is very rare, and a limited number of cases have been presented on this subject. In addition, it will contribute to the literature since there are fewer than ten LCH cases with thyroid involvement.